In US Drug Pricing Debate, ICER’s Voice Gets Louder
The Biggest Mistake For Pharma Is Failing To Engage With ICER
Executive Summary
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
You may also be interested in...
AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
The Other Pandemic
When Novo Nordisk’s anti-obesity medicine Wegovy launched in June 2021, patients and physicians could not get enough. As COVID-19 underscored the risks of obesity, along came the most effective drug yet – on a par with surgery, in terms of weight loss achieved. Pharma’s interest in this disease has reawakened, and Wegovy may be just the first of a new generation of more powerful anti-obesity medicines.